To further examine the involvement of the ERK signaling pathways in CML/RAGE signaling axis, we assessed the phosphorylation of ERK and NFκB following treatment with the ERK inhibitor U0126. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.